Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

ClinicalTrials.gov ID: NCT01858519

Public ClinicalTrials.gov record NCT01858519. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors

Study identification

NCT ID
NCT01858519
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
AbbVie
Industry
Enrollment
1,310 participants

Conditions and interventions

Interventions

Not listed

Eligibility (public fields only)

Age range
2 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2013
Primary completion
Aug 31, 2016
Completion
Aug 31, 2016
Last update posted
Dec 8, 2020

2013 – 2016

United States locations

U.S. sites
47
U.S. states
28
U.S. cities
44
Facility City State ZIP Site status
Site Reference ID/Investigator# 116382 Anchorage Alaska 99508
Site Reference ID/Investigator# 116444 Little Rock Arkansas 72202
Site Reference ID/Investigator# 116595 Long Beach California 90806
Site Reference ID/Investigator# 116855 Los Angeles California 90027
Site Reference ID/Investigator# 116879 Los Angeles California 90027
Site Reference ID/Investigator# 116448 Los Angeles California 90033
Site Reference ID/Investigator# 154681 Denver Colorado 80206-2761
Site Reference ID/Investigator# 116441 Hartford Connecticut 06106
Site Reference ID/Investigator# 127584 New Haven Connecticut 06510
Site Reference ID/Investigator# 116440 Gainesville Florida 32610
Site Reference ID/Investigator# 116882 Miami Florida 33136
Site Reference ID/Investigator# 116277 Orlando Florida 32803
Site Reference ID/Investigator# 116435 Tampa Florida 33606
Site Reference ID/Investigator# 131935 Atlanta Georgia 30125
Site Reference ID/Investigator# 116452 Boise Idaho 83712
Site Reference ID/Investigator# 116442 Chicago Illinois 60611-2291
Site Reference ID/Investigator# 116465 Maywood Illinois 60153
Site Reference ID/Investigator# 141881 Niles Illinois 60714
Site Reference ID/Investigator# 127295 Peoria Illinois 61603
Site Reference ID/Investigator# 116877 Indianapolis Indiana 46202
Site Reference ID/Investigator# 116436 Wichita Kansas 67214
Site Reference ID/Investigator# 136816 Louisville Kentucky 40202
Site Reference ID/Investigator# 116450 New Orleans Louisiana 70112
Site Reference ID/Investigator# 116455 Shreveport Louisiana 71103
Site Reference ID/Investigator# 116461 Boston Massachusetts 02115
Site Reference ID/Investigator# 116463 Grand Rapids Michigan 49503
Site Reference ID/Investigator# 116445 Jackson Mississippi 39216
Site Reference ID/Investigator# 116883 Omaha Nebraska 68198
Site Reference ID/Investigator# 116876 Buffalo New York 14222
Site Reference ID/Investigator# 130461 New Hyde Park New York 11040
Site Reference ID/Investigator# 116449 Syracuse New York 13210
Site Reference ID/Investigator# 116458 Cincinnati Ohio 45267-0564
Site Reference ID/Investigator# 116276 Toledo Ohio 43606
Site Reference ID/Investigator# 116464 Oklahoma City Oklahoma 73104
Site Reference ID/Investigator# 116457 Hershey Pennsylvania 17033
Site Reference ID/Investigator# 116880 Philadelphia Pennsylvania 19104
Site Reference ID/Investigator# 116467 Philadelphia Pennsylvania 19134
Site Reference ID/Investigator# 116466 Pittsburgh Pennsylvania 15224
Site Reference ID/Investigator# 116462 Charleston South Carolina 29425
Site Reference ID/Investigator# 116453 Sioux Falls South Dakota 57105
Site Reference ID/Investigator# 116875 Knoxville Tennessee 37916
Site Reference ID/Investigator# 116856 Houston Texas 77030
Site Reference ID/Investigator# 116459 Tyler Texas 75708
Site Reference ID/Investigator# 116278 Norfolk Virginia 23507
Site Reference ID/Investigator# 116460 Richmond Virginia 23219
Site Reference ID/Investigator# 116438 Morgantown West Virginia 26506
Site Reference ID/Investigator# 116439 Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01858519, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 8, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01858519 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →